The role of CD4+T cells in BKV-specific T cell immunity

Medical Microbiology and Immunology

Volumn 203, Issue 6, 2014, Pages 395-408

  Weist, B J D ^a,b   Schmueck, M ^a,b   Fuehrer, H ^a,b   Sattler, A ^a,b   Reinke, P ^a,b   Babel, N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

Adoptive; BKV; CD4; Kidney transplantation; T cell

Indexed keywords

CD137 ANTIGEN; CD40 LIGAND; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; L SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; BK VIRUS; BK VIRUS INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; CYTOTOXICITY; GRAFT RECIPIENT; IMMUNOLOGY; POLYOMAVIRUS INFECTION; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS INFECTION;

BK VIRUS; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; T-LYMPHOCYTE SUBSETS; TRANSPLANT RECIPIENTS; TUMOR VIRUS INFECTIONS;

EID: 84912014996     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0348-z     Document Type: Article

References (57)

1. Knowles WA (2006) Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 577:19–45
2. Binet I et al (1999) Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 67(6):918–922
3. Hirsch HH (2002) Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2(1):25–30
4. Hirsch HH et al (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347(7):488–496
5. Akazawa Y et al (2012) Fatal BK virus pneumonia following stem cell transplantation. Transpl Infect Dis 14(6):E142–E146
6. Breuer S et al (2012) Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther 16(2):63–77
7. Bogdanovic G et al (2004) Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol 42(11):5394–5396
8. Babel N, Volk HD, Reinke P (2011) BK polyomavirus infection and nephropathy: the virus–immune system interplay. Nat Rev Nephrol 7(7):399–406
9. Bernhoff E et al (2008) Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 8(7):1413–1422
10. Hirsch HH, Steiger J (2003) Polyomavirus BK. Lancet Infect Dis 3(10):611–623
11. Ho ES et al (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11(3):383–393
12. Ramos E et al (2009) The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 87(5):621–630
13. Mueller K et al (2011) BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 91(1):100–107
14. Trydzenskaya H et al (2011) Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation 92(11):1269–1277
15. Zhou W et al (2007) Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol 20(3):379–388
16. Berger C et al (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118(1):294–305
17. Bleakley M, Turtle CJ, Riddell SR (2012) Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol 5(4):409–425
18. Gerdemann U et al (2013) Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21(11):2113–2121
19. Brestrich G et al (2009) Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 9(7):1679–1684
20. Mackinnon S et al (2008) Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 40(1):63–67
21. Peggs KS et al (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362(9393):1375–1377
22. Blyth E et al (2011) BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 92(10):1077–1084
23. Comoli P et al (2003) Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 14(12):3197–3204
24. Geyeregger R et al (2013) Short-term in vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One 8(4):e59592
25. Zandvliet ML et al (2011) Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 34(3):307–319
26. Brestrich G et al (2009) Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 32(9):932–940
27. Rambal V et al (2014) Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Med Microbiol Immunol 203(1):35–45
28. Wolfl M et al (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1):201–210
29. Frentsch M et al (2005) Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 11(10):1118–1124
30. Zandvliet ML et al (2009) Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy. J Immunother 32(5):513–523
31. Wehler TC et al (2008) Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods 339(1):23–37
32. Dong J et al (2007) IL-10 is excluded from the functional cytokine memory of human CD4+ memory T lymphocytes. J Immunol 179(4):2389–2396
33. Hoffmeister B et al (2003) Detection of antigen-specific T cells by cytokine flow cytometry: the use of whole blood may underestimate frequencies. Eur J Immunol 33(12):3484–3492
34. Schmueck M et al (2012) Preferential Expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells. J Immunol 188(10):5189–5198
35. Hammer MH et al (2005) HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol 35(7):2250–2258
36. Hermans IF et al (2004) The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 285(1):25–40
37. Schachtner T et al (2011) BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 11(11):2443–2452
38. Dziubianau M et al (2013) TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am J Transplant 13(11):2842–2854
39. Kiecker F et al (2004) Analysis of antigen-specific T-cell responses with synthetic peptides—what kind of peptide for which purpose? Hum Immunol 65(5):523–536
40. Comoli P et al (2008) T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 31(6):529–536
41. Lindqvist CA et al (2011) Both CD4+ FoxP3+ and CD4+ FoxP3− T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 133(3):296–306
42. Jagger AL et al (2012) FAS/FAS-L dependent killing of activated human monocytes and macrophages by CD4+CD25− responder T cells, but not CD4+CD25+ regulatory T cells. J Autoimmun 38(1):29–38
43. Ramaswami B et al (2011) The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response. Clin Vaccine Immunol 18(5):815–824
44. Jellison ER, Kim SK, Welsh RM (2005) Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 174(2):614–618
45. Frentsch M et al (2013) CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood 122(3):405–412
46. Stark R et al (2013) IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells. Eur J Immunol 43(6):1511–1517
47. Romer PS et al (2011) Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118(26):6772–6782
48. Rogers PR et al (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15(3):445–455
49. Qui HZ et al (2011) CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 187(7):3555–3564
50. Monney L et al (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415(6871):536–541
51. Jelley-Gibbs DM et al (2005) Repeated stimulation of CD4 effector T cells can limit their protective function. J Exp Med 201(7):1101–1112
52. Sallusto F et al (1999) Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708–712
53. Sallusto F et al (2014) Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. J Immunol 192(3):840–844
54. Fuller MJ et al (2004) Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol 172(7):4204–4214
55. Schmueck M et al (2012) Preferential expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4+ T cells. J Immunol 188(10):5189–5198
56. Balduzzi A et al (2011) Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46(7):987–992
57. Feuchtinger T et al (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134(1):64–76